An observational study in Glioblastoma, sponsored by CANbridge Life Sciences Ltd.. Status unknown. Per ClinicalTrials.gov, last updated 2017-09-21.
Sponsored by CANbridge Life Sciences Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
This study's planned enrollment of 62 is close to the median of 60 across 208 observational studies indexed under Glioblastoma.
Browse Glioblastoma studies →CANbridge Life Sciences Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Chinese GBM patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CD95 Ligand Positive Rate
Time frame: 0 day
CpG2 Positive Rate
Time frame: 0 day
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2017; primary completion for Dec 2017, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CANbridge Life Sciences Ltd.